03.24.25 -- AI Performance Management In Biologic And Drug Development

Agentic AI is the next artificial-intelligence iteration for the biopharma industry. It propels prediction to autonomous decision-making. It can usher in transformative efficiencies to CDMOs. If you've day-dreamed of more effective external-support, this may be a ticket to that destination.

Evaluate the strengths and limitations of each bioanalysis method carefully to choose the most effective strategy for your clinical study.

What are the key elements in the readiness stage of a technology transfer that are critical to your success? Explore Process Performance Qualification (PPQ) and the execution stage of PDA TR-65.

An experienced CDMO partner can help bridge the gap from lab scale to clinical and commercial scale while sharing the critical insights needed to launch a biologic manufacturing program.

Consider these important initial steps that should be implemented during the process design phase as a pre-requisite to a successful PPQ campaign and readiness for commercial manufacturing.

Dive into the evolution and future potential of microbial manufacturing in the biopharmaceutical industry to discover how digital tools can revolutionize development and production processes.

Examine why it is essential for biotechs to choose the right contract development and manufacturing partner for drug development success in this market landscape.

In this interview, Dr. Srinivasan Shanmugam of Adare Pharma Solutions discusses the challenges, considerations, and impact of GLP-1 analogs for obesity therapy.

Looking to improve the resilience of your supply chain? Who isn’t? According to a report by Bain & Company, improving supply chain resilience will require redundancy, adaptability, and predictability.

Discover how robotic gloveless isolator sterile fill-finish (SFF) systems can accelerate early-phase drug development, ensuring enhanced sterility and streamlined processes for biopharma innovation.

Pharmaceutical labeling and kitting are critical for ensuring drug safety, compliance, and efficiency. Utilize our advanced technology and regulatory adherence to streamline these processes.

Learn how the right partner can leverage years of experience, market knowledge, industry relationships, and clinical packaging expertise to develop a sourcing strategy tailored to the needs of each study.

Our PAD program streamlines early development to maximize yields, leveraging vaccine expertise, robust expression platforms, and high-quality Vero and Quail cell lines.

As vesicular carriers, exosomes enable cell communication and are key to therapies involving cargo properties, targeting, and tissue-specific sources.